10 IPOs entered the public market this past week headlined by Airbnb (ABNB) and DoorDash (DASH), which completed the largest and second-largest IPOs of 2020, respectively. They were joined by 20 blank check IPOs in the...read more
AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, raised $483 million by offering 24.2 million shares at $20, above the upwardly revised range of $17 to $18. The company offered 1.2 million more shares than...read more
AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, raised the proposed deal size for its upcoming IPO on Thursday. The Vancouver, Canada-based company now plans to raise $403 million by offering 23 million...read more
AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, announced terms for its IPO on Monday.
The Vancouver, Canada-based company plans to raise $357 million by offering 23 million shares at a price range of $14 to...read more
US IPO Weekly Recap: Airbnb and DoorDash make their public debuts in a 10 IPO week
10 IPOs entered the public market this past week headlined by Airbnb (ABNB) and DoorDash (DASH), which completed the largest and second-largest IPOs of 2020, respectively. They were joined by 20 blank check IPOs in the...read more
AI drug discovery platform AbCellera prices upsized IPO at $20, above the upwardly revised range
AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, raised $483 million by offering 24.2 million shares at $20, above the upwardly revised range of $17 to $18. The company offered 1.2 million more shares than...read more
AI drug discovery platform AbCellera raises range to $17 to $18 ahead of $403 million IPO
AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, raised the proposed deal size for its upcoming IPO on Thursday. The Vancouver, Canada-based company now plans to raise $403 million by offering 23 million...read more
AI drug discovery platform AbCellera sets terms for $357 million IPO
AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, announced terms for its IPO on Monday. The Vancouver, Canada-based company plans to raise $357 million by offering 23 million shares at a price range of $14 to...read more